EPHX2 and Other metabolic disease: sEH inhibition prevents cardiac hypertrophy in experimental models based on angiotensin II infusion (Ai et al., 2009), aortic banding (Xu et al., 2006), renovascular hypertension (two kidney one clip) (Gao et al., 2011; Wang Z. H. et al., 2013) and metabolic disease related to obesity and insulin resistance (Roche et al., 2015a).